# Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

> **NCT00384033** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 638 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Desvenlafaxine Succinate Sustained-Release (DVS SR)
- **DRUG:** Desvenlafaxine Succinate Sustained-Release (DVS SR)
- **DRUG:** Placebo
- **DRUG:** Duloxetine 60 mg/day

## Key facts

- **NCT ID:** NCT00384033
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 638 (ACTUAL)
- **Last updated:** 2012-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384033, "Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00384033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*